Trading Halt
Filed with ASX · · 2 pages · English
On 6ix: 6ix.com/news/trading-halt-555
Trading in the securities of Neurizon Therapeutics Limited (‘NUZ’) will be halted at the request of NUZ, pending the release of an announcement by NUZ. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Tuesday, 23 December 2025; or NUZ’s request for a trading halt is attached below for the information of the marke
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
- Neurizon Completes GMP Tablet Registration Batches
- Elanco executive appointed as Neurizon's Board Observer
- Neurizon to present Q1 FY2026 Results
- Australian Patent Granted for NUZ-001
Later from Neurizon Therapeutics
- Equity Raising Presentation
- New Funding Secured for HEALEY ALS Platform Trial
- Regulatory and Development Update
- Global Trademark Protection Secured Across Key Markets
- Neurizon Completes Entitlement Offer
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics